RGEN Stock Performance, Insider Transaction and News

RGEN - Repligen Corporation

Market Cap	9.49B	P/E	57.59	EPS this Y	-18.90%	Ern Qtrly Grth	-83.40%
Income	-1.9M	Forward P/E	65.32	EPS next Y	27.50%	50D Avg Chg	7.00%
Sales	602.35M	PEG	6.98	EPS past 5Y	4.58%	200D Avg Chg	-
Dividend	N/A	Price/Book	4.89	EPS next 5Y	14.71%	52W High Chg	-35.00%
Recommedations	1.90	Quick Ratio	5.35	Shares Outstanding	56.01M	52W Low Chg	27.00%
Insider Own	6.53%	ROA	0.20%	Shares Float	52.21M	Beta	0.95
Inst Own	104.93%	ROE	-0.10%	Shares Shorted/Prior	3.92M/4.40M	Price	170.48
Gross Margin	47.70%	Profit Margin	-0.32%	Avg. Volume	612,325	Target Price	193.32
Oper. Margin	1.60%	Earnings Date	Oct 29	Volume	1,177,969	Change	2.01%

Healthcare | Medical Instruments & Supplies | United States

About Repligen Corporation

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation News

11/13/24	Company News for Nov 13, 2024
11/13/24	Q3 2024 Repligen Corp Earnings Call
11/13/24	Repligen Corp (RGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
11/12/24	Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
11/12/24	Repligen Stock Soars 10% on Record Growth and Bold Moves
11/12/24	Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
11/12/24	Repligen: Q3 Earnings Snapshot
11/12/24	Repligen Reports Third Quarter 2024 Financial Results
11/05/24	Repligen Corporation to Present at Upcoming Investor Conferences
10/31/24	Repligen to Report Third Quarter 2024 Financial Results
10/23/24	Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10/22/24	Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
10/21/24	US Stocks Estimated Below Intrinsic Value In October 2024
10/15/24	3 investable themes, categories outside of the AI trade
06:30 AM	Repligen Opens Training & Innovation Center to Elevate Customer Experience
09/11/24	Several Headwinds Dragged Repligen Corporation (RGEN) in Q2
09/09/24	Reasons for the Decline of Repligen (RGEN) in Q2
09/07/24	Repligen Corporation (RGEN) Fell Due to CEO Transition
08/29/24	Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?
08/29/24	Repligen Corporation (NASDAQ:RGEN) Shares Could Be 23% Below Their Intrinsic Value Estimate

RGEN Chatroom

Kelsey_King Posted - 2 days ago

🚨 MYNZ Petra Brand Ambassador says to keep an eye on "BIG NEWS from the NFL." This is going to run parabolic soon, right after the healthcare giant Thermo Fisher ($210B mkt cap) partnered with Mainz to develop and launch together ColoAlert in US 🚀 Buy the dip now, the train is leaving very soon. $LEGN $RGEN $MDGL

Estimize Posted - 3 days ago

Wall St is expecting 0.41 EPS for $RGEN Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

SamsonGray Posted - 4 days ago

$LEGN $RGEN LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

LvivCrypto Posted - 4 days ago

[$LEGN $RGEN] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

Rozer900 Posted - 6 days ago

$RGEN Repligen’s bioprocessing technologies continue to drive its strong position in life sciences and biotech manufacturing!

Wigglyick Posted - 1 week ago

That didn’t age well $RGEN

kylevallans Posted - 1 week ago

$RGEN

Wigglyick Posted - 1 week ago

$RGEN small tracker started at the close.

swingingtech Posted - 1 week ago

$MOS $RGEN $SE $FOUR https://wallstreetwaves.com/latest-updates-from-our-company-november-13-2024/

JackDarwin Posted - 1 week ago

$RGEN Bullish Gap Up Formed With good Volume. https://www.stockaio.com/US/ai/Stock/RGEN/Candlestick

Benzinga Posted - 1 week ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth https://www.benzinga.com/general/health-care/24/11/41914004/repligen-q3-earnings-beat-expectations-highlights-improving-market-conditions-analyst-says-well-positioned-for-long-term-growth $RGEN

MoniBarnett Posted - 1 week ago

💥 Boom 🚨 Big news! LFGOOOOOO! Mainz Biomed MYNZ has teamed up with Thermo Fisher TMO (mkt cap $209.2B, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B annual revenue and advanced tech will boost MYNZ’s mRNA-based assays, hitting 85% detection for advanced adenomas vs. competitors’ 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Win-win for both sides — TMO stepping into the CRC market too. Big developments ahead! Calling all apes, let's crush these shorties—this time is bull time. Insane news, we've been waiting for!!! $LEGN $RGEN

OpenOutcrier Posted - 1 week ago

$RGEN (+7.4% pre) Repligen Reports Third Quarter 2024 Financial Results https://ooc.bz/l/47757

DonCorleone77 Posted - 1 week ago

$RGEN Repligen sees FY24 adjusted EPS $1.50-$1.58, consensus $1.43 Sees FY24 revenue $630M-$639M, consensus $628.98M

DonCorleone77 Posted - 1 week ago

$RGEN Repligen reports Q3 adjusted EPS 43c, consensus 33c Reports Q3 revenue $154.871M, consensus $153.23M. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "I'm pleased to report strong third quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and equipment sales in the quarter, with each delivering year-over-year and sequential growth. In new modalities, we achieved record sales in the quarter and our differentiated technology continues to serve us well. We are further encouraged by continued strength in Filtration, consumables, and Pharma, as well as order recovery in Chromatography. With clear line of sight, we are narrowing the 2024 revenue guidance shared in our September update, maintaining the midpoint, and we are optimistic about our opportunity funnel as we move into 2025."

Estimize Posted - 1 week ago

$RGEN reported - EPS and - revenue for Q3. http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_content=RGEN&utm_medium=

Quantumup Posted - 2 weeks ago

BofA⬆️PT $JANX $65 was $59/Buy+⬆️PoS '007 (44% to 50%)/'008 (34% to 38%), after 3Q24💰wrap-up. BofA⬆️PT on compelling TRACTr programs w/ potential best-in-class (BiC) profiles ahead of major de-risking🔬in the near term: $nvo $amgn $jnj $rgen Also Mentioned in BofA's 3Q24 Earnings Wrap-up: alec xncr ymab rgnx rxrx ntla crbu sana

Optionshmoptions Posted - 2 weeks ago

$RGEN tf is wrong with this now

Stocksrunner Posted - 2 weeks ago

$RGEN preps for earnings tomorrow. After a miss last time, investors are hopeful for a comeback. With an implied 42.93% upside, will guidance be the key?

Estimize Posted - 10/31/24

$RGEN confirmed to report on 11/12 BMO

Estimize Posted - 10/28/24

Wall St is expecting 45.42% YoY EPS growth for $RGEN in Q3, up from -37.74% in Q2 [Reporting Tomorrow 10/29 BMO] http://www.estimize.com/in